HLS Therapeutics Inc.
HLTRF
$3.47
-$0.07-2.06%
OTC PK
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -4.66% | 12.26% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -4.66% | 12.26% | |||
| Cost of Revenue | -1.60% | 0.97% | |||
| Gross Profit | -5.81% | 17.19% | |||
| SG&A Expenses | -0.54% | -0.44% | |||
| Depreciation & Amortization | 0.51% | 2.29% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -0.43% | 0.91% | |||
| Operating Income | -76.61% | 64.49% | |||
| Income Before Tax | -57.46% | 43.96% | |||
| Income Tax Expenses | -107.02% | 1,152.17% | |||
| Earnings from Continuing Operations | -42.94% | 38.21% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -42.94% | 38.21% | |||
| EBIT | -76.61% | 64.49% | |||
| EBITDA | -12.07% | 48.47% | |||
| EPS Basic | -44.11% | 37.92% | |||
| Normalized Basic EPS | -58.50% | 43.67% | |||
| EPS Diluted | -38.67% | 35.71% | |||
| Normalized Diluted EPS | -58.50% | 43.67% | |||
| Average Basic Shares Outstanding | -0.75% | -0.48% | |||
| Average Diluted Shares Outstanding | -0.75% | -0.48% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||